ModifiedUnitedHealthcarePolicy CS064LA.O

Intensity-Modulated Radiation Therapy (for Louisiana Only)

Medical policy governing coverage of IMRT for adults 19+ in Louisiana, specifying proven, conditional, and not medically necessary indications and applicable coding guidance. Affects providers and members of UnitedHealthcare Community Plan in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for Louisiana Only)

Policy CodePolicy CS064LA.O

Change TypeRevised indications and clarified sections

Effective DateJune 1, 2025

Next Review DateN/A

Key ActionWhen requesting IMRT for non-listed indications, provide a comparison of IMRT and non-IMRT treatment plans demonstrating clinically meaningful reduction in normal tissue dose.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Archived previous policy version CS064LA.N.

19+applies to individuals aged

Up to 10 fxHA-WBRT fraction limit

Louisianastate-specific

30 Gy/10fx

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

recommended HA-WBRT dose

77301, 77385...example codes listed

Coverage Criteria for IMRT

inv-01: Proven/Medically Necessary Indications — Covered when treating the primary site with definitive intent for the following diagnoses in individuals 19 years and older:

Proven/Medically Necessary Indications — Covered when treating the primary site with definitive intent for the following diagnoses in individuals 19 years and older:

ANY of the following

Anal/anal canal cancer
Breast cancer when one of the following applies: the left-sided internal mammary nodes are being treated; or accelerated partial breast irradiation of up to 5 fractions
Central nervous system (CNS) tumors (primary or benign) including brain, brainstem, and spinal cord
Cervical cancer
Endometrial cancer
Esophageal cancer
Head and neck cancers, including lymphoma and solitary plasmacytomas, when treatment includes pharynx (nasopharynx, oropharynx, hypopharynx), larynx (stage III or IV glottic cancer), salivary glands, oral cavity (includes tongue), nasal cavity, paranasal sinuses
Mediastinal tumors (e.g., lymphomas, thymomas), including tracheal cancer
Non-small cell lung cancer, stage III, undergoing chemoradiation therapy
Pancreatic cancer
Prostate cancer
Vulvar cancer
Compensator-based beam modulation treatment when done in combination with an IMRT indication listed above
Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) of up to 10 fractions for brain metastases when criteria for HA-WBRT are met (see hippocampal-avoidance criteria group)

inv-02: Case-by-case (exception) coverage — Exceptions / case-by-case coverage when at least one condition is met:

Case-by-case (exception) coverage — Exceptions / case-by-case coverage when at least one condition is met:

ALL of the following

ONE of
- Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity, as specified by RTOG or QUANTEC guidelines, demonstrated on a comparison of treatment plans for IMRT vs a non-IMRT technique (e.g., 3D conformal plan)
- The same or an immediately adjacent area has previously been irradiated and the dose distribution must be sculpted to avoid exceeding cumulative normal tissue tolerance
Requests must include clinically appropriate radiation dose and treatment planning comparisons or prior radiation dose history to support the exception

inv-03: Covered with clinical criteria (evidence & guideline supported) — Summary of clinical indications and evidence supporting IMRT/VMAT use:

Covered with clinical criteria (evidence & guideline supported) — Summary of clinical indications and evidence supporting IMRT/VMAT use:

ANY of the following

Anal Cancer
- Retrospective and prospective data (Jhaveri et al., 2018; RTOG 0529) show IMRT/DP-IMRT is associated with reduced toxicity and similar or improved long-term outcomes compared with non-IMRT techniques; guidelines (ACR, ESMO, NCCN) recommend IMRT/VMAT for anal cancer
Breast Cancer
- Randomized trial of APBI-IMRT (Meattini et al., 2020) demonstrated low ipsilateral recurrence and reduced acute/late toxicity and improved cosmesis with 5-fraction APBI using IMRT; IMRT with DIBH reduces cardiac dose when internal mammary nodes are targeted (Jagsi et al., 2018)
Central Nervous System Tumors

inv-04: COVERAGE CRITERIA — Guideline-based coverage stance and contexts where IMRT is recommended

COVERAGE CRITERIA — Guideline-based coverage stance and contexts where IMRT is recommended:

ALL of the following

IMRT/VMAT is recommended by professional guidelines for disease sites where dose conformity reduces exposure to critical organs at risk and decreases acute or late toxicity (e.g., head and neck, CNS, anal, breast when internal mammary nodes targeted, cervical/endometrial pelvic treatments, mediastinal lymphoma, stage III NSCLC, prostate, pancreatic, vulvar)
When using IMRT, appropriate image-guidance (IGRT), motion management (e.g., DIBH, respiratory gating), and adherence to established dose constraints (RTOG/QUANTEC/NCCN) are required to ensure safe delivery
IMRT should not be used as a routine alternative to brachytherapy for treatment of central disease in individuals with an intact cervix

inv-05: Site-specific coverage rationale — Covered when clinically justified per site-specific evidence and guideline recommendations:

Site-specific coverage rationale — Covered when clinically justified per site-specific evidence and guideline recommendations:

ANY of the following

Hippocampal-Avoidance WBRT
- HA-WBRT + memantine is supported for patients with brain metastases when criteria for patient selection and hippocampal exclusion zones are met (see hippocampal-avoidance criteria group)
Head and Neck
- IMRT is supported to spare salivary glands, temporal lobes, auditory structures, optic structures and other OARs to reduce long-term toxicity while maintaining tumor control
Esophagus
- IMRT may be used to reduce heart and lung dose when 3D techniques cannot achieve acceptable OAR sparing; dose escalation beyond standard 50.4 Gy has not shown clear benefit

inv-06: Hippocampal-Avoidance WBRT coverage conditions — HA-WBRT + memantine is supported when ALL of the following are met

Hippocampal-Avoidance WBRT coverage conditions — HA-WBRT + memantine is supported when ALL of the following are met:

ALL of the following

Adult patient (≥ 19 years) with brain metastases being considered for whole-brain radiotherapy
No leptomeningeal disease
No metastases within the hippocampal-avoidance region (approximately within 5 mm of the hippocampus)
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or Karnofsky performance status (KPS) ≥ 70
Prognosis of ≥ 4 months

inv-07: IMRT and advanced RT technique coverage considerations — Use of IMRT (or other advanced techniques) is supported when ALL of the following are applicable

IMRT and advanced RT technique coverage considerations — Use of IMRT (or other advanced techniques) is supported when ALL of the following are applicable:

ALL of the following

The prescribed radiation dose and fractionation are clinically appropriate for the disease site and intent of therapy
A comparison plan demonstrates that non-IMRT techniques would result in clinically meaningful increased dose to critical normal structures, or prior radiation necessitates highly conformal planning to avoid cumulative overdose
The treating facility documents availability of necessary technology (IMRT/VMAT planning and delivery systems, IGRT, motion management) and quality assurance processes
Treatment planning adheres to established dose constraints (e.g., RTOG, QUANTEC, and site-specific guideline constraints) and documents OAR doses and expected benefits

inv-08: Covered with criteria by disease site — IMRT is supported by evidence and guideline statements for the following indications when standard radiation therapy is indicated:

Covered with criteria by disease site — IMRT is supported by evidence and guideline statements for the following indications when standard radiation therapy is indicated:

ANY of the following

Anal cancer — IMRT/DP-IMRT reduces toxicity and is preferred by guidelines
Breast cancer — IMRT-APBI (5 fractions) and IMRT with DIBH for left-sided/intern mammary node treatments
Central nervous system tumors — IMRT/VMAT recommended for conformal treatment and OAR sparing
Cervical and endometrial cancer — IMRT preferred for pelvic treatment to reduce acute and late toxicity; not a routine alternative to brachytherapy for intact cervix central disease

Applicable Procedure and Billing Codes

Applicable CPT/HCPCS Codesmixed

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex
G6001	Ultrasonic guidance for placement of radiation therapy fields.

1–10 of 13

1/2

HCPCS Code (not on state fee schedule flagged)HCPCS

G6017

Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment

Authorization, Documentation, and Provider Requirements

Prior Authorization

Guideline-supported prior authorization rationale

Guideline-supported rationale: Multiple professional guidelines (NCCN, ASTRO, ACR, ESMO) support preferential use of IMRT/VMAT over 3D-CRT for specific tumor sites (e.g., anal carcinoma, IDH‑mutant diffuse glioma, cervical and endometrial cancers, head & neck cancers, esophageal cancer, stage III NSCLC, select breast scenarios, prostate, pancreas, vulvar, and CNS tumors). These guidelines cite reduced acute and late toxicity and improved organ-at-risk (OAR) sparing while maintaining tumor control. When IMRT/VMAT is unavailable, guideline-consistent alternatives such as 3D‑CRT are acceptable for some indications.

Use guidelines to support prior authorization for listed proven indications.
If IMRT/VMAT is not available, document use of guideline-recommended alternatives (e.g., 3D‑CRT).

Documentation Required

Prior authorization: document clinical indications and planning constraints

Document clinical indications and planning constraints for prior authorization: For proven indications or exception requests, include clinical history (tumor site, stage, prior irradiation, performance status, prognosis), rationale for modality selection, and specific planning objectives/constraints demonstrating OAR sparing. When requesting IMRT as an exception, provide a comparison of IMRT and non‑IMRT (e.g., 3D‑CRT) treatment plans showing clinically meaningful reductions in dose to normal tissues (per RTOG/QUANTEC or guideline constraints) or evidence that re‑irradiation requires sculpting to avoid cumulative OAR tolerance exceedance.

Definitions

Definitive Therapy — Radiation treatments for cancer with a curative intent.

DefinitionRadiation treatments for cancer with a curative intent.

Applies toDefinitive therapy of the primary site as listed in policy (see Proven/Medically Necessary Indications).

Policy updateDefinition of 'Definitive Therapy' updated in policy revision effective 06/01/2025.

IMRT/VMAT — Advanced conformal radiation therapy techniques that modulate beam intensity or use volumetric arc delivery to better spare adjacent norm...

DefinitionAdvanced conformal radiation therapy techniques that modulate beam intensity or use volumetric arc delivery to better spare adjacent normal tissues and organs-at-risk.

Examples

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy (for Louisiana Only)

Policy CodePolicy CS064LA.O

Change TypeRevised indications and clarified sections

Effective DateJune 1, 2025

Next Review DateN/A

Key ActionWhen requesting IMRT for non-listed indications, provide a comparison of IMRT and non-IMRT treatment plans demonstrating clinically meaningful reduction in normal tissue dose.

SourceLink

On This Page

Multiple cohort, RCT, and guideline sources (Mills et al., 2024; Chen et al., 2022; Milker-Zabel et al., 2007; ASTRO, NCCN) support IMRT/VMAT for improved target conformity and reduced toxicity for gliomas, meningiomas, and other CNS tumors

Cervical and Endometrial Cancer

ASTRO and NCCN endorse IMRT to decrease acute and chronic toxicity in postoperative and definitive settings; IMRT should not replace brachytherapy for intact cervix central disease

Esophageal Cancer

RCT evidence (Hulshof et al., 2021) shows no benefit to dose escalation beyond 50.4 Gy; meta-analyses and dosimetric studies indicate IMRT reduces heart and lung dose and may improve OS in some analyses

Head and Neck Cancer

Randomized and prospective studies demonstrate IMRT reduces xerostomia and other late toxicities without compromising tumor control (Nutting et al., 2011; Gupta et al., 2020; Nutting et al., 2023); NCCN prefers IMRT to spare critical OARs

Hippocampal-Avoidance WBRT

Phase III trials (Brown et al., 2020; Gondi et al., 2024) demonstrate HA-WBRT + memantine preserves cognitive function versus WBRT + memantine for eligible patients; NCCN recommends HA-WBRT + memantine for selected patients

Mediastinal Tumors and Lymphoma

Systematic reviews show IMRT can improve conformity and reduce high-dose exposure to OARs though may increase low-dose bath; NCCN recommends considering advanced modalities when clinically advantageous

NSCLC Stage III

Secondary analyses of RTOG 0617 support IMRT for reduced cardiopulmonary toxicity with similar oncologic outcomes; NCCN prefers IMRT in this setting

Pancreatic Cancer

ASTRO 2019 guideline recommends modulated techniques (IMRT/VMAT) for localized pancreatic cancer (strong recommendation); NCCN notes IMRT is increasingly applied to improve PTV coverage and spare OARs

Prostate Cancer

Multiple society guidelines (ACR, AUA/ASTRO, NCCN) identify IMRT as a standard EBRT technique for prostate cancer and for pelvic nodal irradiation

Vulvar Cancer

ESGO and NCCN recommend IMRT with daily IGRT/verification to maximize target dose and minimize normal tissue exposure

NSCLC Stage III

IMRT is supported for locally advanced disease with chemoradiation to reduce high-grade pneumonitis and cardiac dose when appropriate

Pelvic Malignancies (Cervical/Endometrial/Prostate/Vulvar)

IMRT is supported to minimize bowel, bladder, hematologic, and other pelvic organ toxicity and is preferred in many guideline-recommended scenarios

Concurrent or planned memantine therapy as per trial protocols and guideline recommendations

Treatment planning and delivery capable of hippocampal contouring and avoidance using IMRT/VMAT with appropriate QA and IGRT

For re-irradiation cases, cumulative dose to normal tissues is documented and supports the need for IMRT to limit toxicity

Esophageal cancer — IMRT may reduce heart and lung dose; dose escalation beyond 50.4 Gy not routinely supported

Head and neck cancers — IMRT reduces xerostomia and other late toxicities while maintaining locoregional control

Mediastinal tumors/lymphoma — IMRT may reduce high-dose exposure to OARs; consider long-term risks and dose constraints

NSCLC stage III — IMRT preferred in chemoradiation to reduce cardiopulmonary toxicity

Pancreatic cancer — IMRT/VMAT recommended by ASTRO and used to improve PTV coverage and spare OARs

Prostate cancer — IMRT is a standard EBRT approach; recommended for pelvic nodal irradiation when indicated

Vulvar cancer — IMRT with daily IGRT is recommended for optimal target coverage and normal tissue sparing

Include prior radiation details and cumulative dose considerations when applicable.
Provide dose‑volume histograms and specific OAR constraints used in planning.

Note

Device approval information

Device approval information (informational): The FDA has cleared multiple devices for IMRT delivery (product codes MUJ and IYE). FDA clearance is informational only and not by itself a basis for coverage decisions.

Refer to the FDA device database for device‑specific information: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm

Prior Authorization

No explicit prior authorization triggers

No explicit prior authorization triggers: This policy does not enumerate automatic denial triggers or universal prior authorization exemptions beyond stated populations and proven indications; requests for IMRT for indications not listed as proven are evaluated case‑by‑case and may require additional documentation or may be denied if exception criteria are unmet.

Confirm payer‑specific prior authorization requirements separately — absence of a trigger here does not remove plan requirements.

Prior Authorization

Prior authorization when OAR sparing is required

OAR‑sparing justification: IMRT (or other advanced modalities such as PBRT) should be selected when reduction of dose to critical OARs cannot be achieved with 3D techniques. Prior authorization should include demonstrable OAR dose reductions and specific constraints targeted for sparing (heart, lungs, bowel, spinal cord, cochlea, optic structures, hippocampi, etc.).

Provide comparative dose‑volume data showing clinically meaningful OAR dose reduction.
List the specific OARs and numeric constraints that drove modality choice.

Denial Risk

Combined IMRT and Proton RT

Combined IMRT and Proton RT: There is no evidence supporting the combined use of IMRT and proton beam RT within a single treatment plan. Requests proposing combined‑modality (simultaneous IMRT + proton) planning should include strong justification and will be subject to individual clinical review; such combined plans may be operationally or clinically inappropriate.

If sequential use of different modalities is proposed, document clinical rationale and timing; simultaneous combination is not supported by evidence.

Prior Authorization

Benefit contract compliance required

Benefit contract compliance required: Coverage determinations must follow federal, state, or contractual benefit plan terms which take precedence over this Medical Policy. Verify applicable benefit terms and prior authorization requirements before initiating treatment. UnitedHealthcare may use third‑party tools (e.g., InterQual) to assist in benefit administration.

Check member‑specific benefit language and state mandates prior to authorization.
Policy guidance is informational and subject to contract terms.

Documentation Required

Guideline-based documentation recommendations

Guideline‑based documentation recommendations: Use guideline statements (NCCN, ASTRO, ACR, ESMO) to support clinical rationale, planning objectives, and OAR constraints. Documentation should reference the applicable guideline recommendations and specific sections that support modality selection, fractionation, and verification requirements.

Cite guideline name, year, and relevant recommendation text or section when submitting prior authorization.

Documentation Required

Image‑guidance and verification documentation

Image‑guidance and verification documentation: Many guidelines (NCCN, ASTRO) state that image‑guided radiation therapy (IGRT) — orthogonal imaging and/or routine volumetric imaging (e.g., cone beam CT) — is essential when delivering IMRT to ensure target coverage and reproducible OAR sparing. Authorization should note planned IGRT frequency and methods (daily CBCT, stereoscopic x‑ray, ultrasound as applicable).

Document IGRT modality (CBCT, stereoscopic x‑ray, ultrasound) and frequency (daily, weekly) used for verification.

Documentation Required

Clinical rationale and documentation to support tumor site and patient factors

Clinical rationale for advanced RT and documentation to support tumor site: Documentation should clearly state the tumor site, proximity to OARs (e.g., hippocampus within 5 mm for HA‑WBRT), prognosis (expected survival ≥ 4 months where indicated), performance status (ECOG ≤ 2 or KPS ≥ 70), absence of leptomeningeal disease when relevant, and any prior radiation. For HA‑WBRT, include rationale that no metastasis lies within 5 mm of the hippocampus and plan to use memantine where indicated.

Include imaging reports delineating tumor location relative to critical OARs.
List performance status and estimated prognosis when relevant to modality choice.

Step Therapy

Alternative therapy sequencing and step therapy

Alternative therapy sequencing and step therapy considerations: Guidelines recommend IMRT/VMAT for many indications but do not mandate explicit step‑therapy sequences; when IMRT/VMAT is unavailable, 3D‑CRT may be an acceptable alternative. There are no uniform step‑therapy rules specified in this policy — coverage decisions should follow contract terms and guideline‑based clinical judgment.

If proposing 3D‑CRT due to resource limitations, document reasons and expected impact on OARs/targets.
No automatic requirement to attempt a less complex modality before IMRT is specified in this policy.

Includes intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).

Guideline basisRecommended by specialty guidelines (ACR, NCCN, ASTRO) for tumors near critical OARs to reduce acute and late toxicity.

DP-IMRT (Dose-painted IMRT) — An IMRT approach that delivers different dose levels to subvolumes (simultaneous integrated boost) based on tumor extent/stage to spare n...

DefinitionDose-painted IMRT (DP-IMRT) delivers different dose levels to subvolumes (simultaneous integrated boost) based on tumor extent or stage to spare normal tissue while escalating dose to gross disease.

Clinical evidenceEvaluated in RTOG 0529 for anal cancer showing reduced acute hematologic, GI, and dermatologic toxicity though primary endpoint unmet; long-term outcomes showed similar tumor control with reduced late high-grade effects.

Guideline supportIMRT/VMAT with SIB techniques are recognized in guidelines (ESMO/NCCN) for analytically sparing OARs and enabling integrated boosts.

IMRT/VMAT/IGRT — Advanced radiation techniques that allow conformal dose distribution (IMRT/VMAT) and image-guided verification (IGRT) to reduce dose to o...

DefinitionCombined use of IMRT/VMAT for conformal dose distribution with IGRT for image-guided verification to ensure accurate target localization and sparing of OARs.

Clinical roleIGRT (orthogonal or volumetric imaging such as cone-beam CT) is emphasized with IMRT to ensure appropriate target coverage and normal tissue sparing.

Guideline supportASTRO and NCCN recommend IMRT/VMAT with image guidance for tumors near critical structures and in postoperative pelvic RT to reduce toxicity.

HA-WBRT — Hippocampal-avoidance whole-brain radiation therapy — a WBRT technique that spares the hippocampi to reduce cognitive decline, often give...

DefinitionHippocampal-avoidance whole-brain radiation therapy (HA-WBRT) is a WBRT technique that spares the hippocampi to reduce cognitive decline, typically delivered with concurrent memantine.

Recommended regimenHA-WBRT plus memantine commonly delivered as 30 Gy in 10 fractions per NCCN guidance and trial protocols.

Eligibility constraintNot appropriate if metastases are within ~5 mm of the hippocampal-avoidance region or for leptomeningeal disease.

DO-IMRT — Dysphagia-optimized IMRT — an IMRT planning approach that reduces dose to pharyngeal constrictor and aspiration-related structures to imp...

DefinitionDysphagia-optimized IMRT (DO-IMRT) is an IMRT planning approach that reduces dose to pharyngeal constrictor and aspiration-related structures to improve swallowing outcomes.

Clinical evidenceA randomized phase 3 trial (Nutting et al. 2023) showed improved swallowing-related patient-reported outcomes with DO-IMRT versus standard IMRT.

Intended benefitDesigned to minimize long-term dysphagia and aspiration risk by prioritizing dose reduction to swallowing structures during planning.

HA-WBRT — Hippocampal-avoidance whole-brain radiotherapy delivered with IMRT techniques to spare the hippocampal neurogenic niche, often given with...

DefinitionHA-WBRT delivered with IMRT techniques spares the hippocampal neurogenic niche and is often combined with memantine to preserve cognitive function.

Supporting trialNRG CC001 (Brown/Gondi et al.) randomized 518 adults to HA-WBRT + memantine versus WBRT + memantine and found reduced cognitive failure with HA-WBRT without detriment to OS or intracranial PFS.

Practical noteCandidate selection requires no metastases within 5 mm of hippocampus and reasonable expected survival (≈≥4 months).

IMRT — Intensity-modulated radiation therapy — an advanced RT technology that sculpts dose to spare organs at risk while treating targets, prefe...

DefinitionIntensity-modulated radiation therapy (IMRT) is an advanced RT technology that sculpts dose distributions to spare organs-at-risk while delivering therapeutic dose to targets.

Clinical applicationWidely used and recommended in guidelines for head and neck, prostate, pancreatic, and many other sites where OAR sparing is clinically important.

Delivery considerationsIMRT planning commonly uses multiple fields or arcs with image guidance and may require plan-specific dose-volume constraints for OARs.

IMRT — Intensity-modulated radiation therapy — an advanced external-beam technique recommended by major specialty guidelines for treating locali...

DefinitionIMRT is an advanced external-beam technique recommended by major specialty guidelines to improve target conformity and spare normal tissues across multiple disease sites.

Guideline endorsementsASTRO, NCCN, ACR, AUA and ESGO guidelines endorse IMRT/VMAT or other advanced techniques for specific indications (e.g., pancreatic, prostate, vulvar, head and neck).

Role in practiceIMRT is used for definitive, postoperative, and palliative scenarios when clinically indicated to reduce toxicity or meet planning constraints.

Definitive Therapy — Definitive Therapy (definition updated in policy).

Definition (updated)Definitive Therapy: Radiation treatments for cancer with a curative intent (definition updated in the 06/01/2025 policy revision).

Policy noteRevision added vulvar cancer and updated terminology to 'anus/anal canal cancer' in the list of proven indications for Definitive Therapy IMRT.

Effective datePolicy revision effective 06/01/2025.